These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

196 related articles for article (PubMed ID: 22916155)

  • 1. Sputum biomarkers and the prediction of clinical outcomes in patients with cystic fibrosis.
    Liou TG; Adler FR; Keogh RH; Li Y; Jensen JL; Walsh W; Packer K; Clark T; Carveth H; Chen J; Rogers SL; Lane C; Moore J; Sturrock A; Paine R; Cox DR; Hoidal JR
    PLoS One; 2012; 7(8):e42748. PubMed ID: 22916155
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sputum club cell protein concentration is associated with pulmonary exacerbation in cystic fibrosis.
    Laguna TA; Williams CB; Brandy KR; Welchlin-Bradford C; Moen CE; Reilly CS; Wendt CH
    J Cyst Fibros; 2015 May; 14(3):334-40. PubMed ID: 25456770
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective multicenter randomized patient recruitment and sample collection to enable future measurements of sputum biomarkers of inflammation in an observational study of cystic fibrosis.
    Liou TG; Adler FR; Argel N; Asfour F; Brown PS; Chatfield BA; Daines CL; Durham D; Francis JA; Glover B; Heynekamp T; Hoidal JR; Jensen JL; Keogh R; Kopecky CM; Lechtzin N; Li Y; Lysinger J; Molina O; Nakamura C; Packer KA; Poch KR; Quittner AL; Radford P; Redway AJ; Sagel SD; Sprandel S; Taylor-Cousar JL; Vroom JB; Yoshikawa R; Clancy JP; Elborn JS; Olivier KN; Cox DR
    BMC Med Res Methodol; 2019 Apr; 19(1):88. PubMed ID: 31027503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sputum desmosine during hospital admission for pulmonary exacerbation in cystic fibrosis.
    Laguna TA; Wagner BD; Luckey HK; Mann SA; Sagel SD; Regelmann W; Accurso FJ
    Chest; 2009 Dec; 136(6):1561-1568. PubMed ID: 19567495
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sputum trypsin-like protease activity relates to clinical outcome in cystic fibrosis.
    Reihill J; Moffitt K; Douglas L; Stuart Elborn J; Jones A; Lorraine Martin S
    J Cyst Fibros; 2020 Jul; 19(4):647-653. PubMed ID: 31932105
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association between pulmonary function and sputum biomarkers in cystic fibrosis.
    Mayer-Hamblett N; Aitken ML; Accurso FJ; Kronmal RA; Konstan MW; Burns JL; Sagel SD; Ramsey BW
    Am J Respir Crit Care Med; 2007 Apr; 175(8):822-8. PubMed ID: 17234902
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Feasibility of Early Detection of Cystic Fibrosis Acute Pulmonary Exacerbations by Exhaled Breath Condensate Metabolomics: A Pilot Study.
    Zang X; Monge ME; McCarty NA; Stecenko AA; Fernández FM
    J Proteome Res; 2017 Feb; 16(2):550-558. PubMed ID: 28152602
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistin is elevated in cystic fibrosis sputum and correlates negatively with lung function.
    Forrest OA; Chopyk DM; Gernez Y; Brown MR; Conrad CK; Moss RB; Tangpricha V; Peng L; Tirouvanziam R
    J Cyst Fibros; 2019 Jan; 18(1):64-70. PubMed ID: 29937317
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proteomic analysis of sputum from adults and children with cystic fibrosis and from control subjects.
    Sloane AJ; Lindner RA; Prasad SS; Sebastian LT; Pedersen SK; Robinson M; Bye PT; Nielson DW; Harry JL
    Am J Respir Crit Care Med; 2005 Dec; 172(11):1416-26. PubMed ID: 16166615
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sputum Candida albicans presages FEV₁ decline and hospital-treated exacerbations in cystic fibrosis.
    Chotirmall SH; O'Donoghue E; Bennett K; Gunaratnam C; O'Neill SJ; McElvaney NG
    Chest; 2010 Nov; 138(5):1186-95. PubMed ID: 20472859
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acute pulmonary exacerbation and lung function decline in patients with cystic fibrosis: high-mobility group box 1 (HMGB1) between inflammation and infection.
    Chirico V; Lacquaniti A; Leonardi S; Grasso L; Rotolo N; Romano C; Di Dio G; Lionetti E; David A; Arrigo T; Salpietro C; La Rosa M
    Clin Microbiol Infect; 2015 Apr; 21(4):368.e1-9. PubMed ID: 25658530
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Predicting disease progression in cystic fibrosis.
    Breuer O; Caudri D; Stick S; Turkovic L
    Expert Rev Respir Med; 2018 Nov; 12(11):905-917. PubMed ID: 30173593
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Metabolomic profiling of regulatory lipid mediators in sputum from adult cystic fibrosis patients.
    Yang J; Eiserich JP; Cross CE; Morrissey BM; Hammock BD
    Free Radic Biol Med; 2012 Jul; 53(1):160-71. PubMed ID: 22580336
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of mortality and timing of referral for lung transplantation in cystic fibrosis patients.
    Augarten A; Akons H; Aviram M; Bentur L; Blau H; Picard E; Rivlin J; Miller MS; Katznelson D; Szeinberg A; Shmilovich H; Paret G; Laufer J; Yahav Y
    Pediatr Transplant; 2001 Oct; 5(5):339-42. PubMed ID: 11560752
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular DNA in sputum is associated with pulmonary function and hospitalization in patients with cystic fibrosis.
    Piva TC; Luft C; Antunes KH; Marostica PJC; Pinto LA; Donadio MVF
    Respir Med; 2020 Oct; 172():106144. PubMed ID: 32937222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potential role of high-mobility group box 1 in cystic fibrosis airway disease.
    Rowe SM; Jackson PL; Liu G; Hardison M; Livraghi A; Solomon GM; McQuaid DB; Noerager BD; Gaggar A; Clancy JP; O'Neal W; Sorscher EJ; Abraham E; Blalock JE
    Am J Respir Crit Care Med; 2008 Oct; 178(8):822-31. PubMed ID: 18658107
    [TBL] [Abstract][Full Text] [Related]  

  • 17. IP-10 is a potential biomarker of cystic fibrosis acute pulmonary exacerbations.
    Solomon GM; Frederick C; Zhang S; Gaggar A; Harris T; Woodworth BA; Steele C; Rowe SM
    PLoS One; 2013; 8(8):e72398. PubMed ID: 23977293
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Long-term treatment with oral N-acetylcysteine: affects lung function but not sputum inflammation in cystic fibrosis subjects. A phase II randomized placebo-controlled trial.
    Conrad C; Lymp J; Thompson V; Dunn C; Davies Z; Chatfield B; Nichols D; Clancy J; Vender R; Egan ME; Quittell L; Michelson P; Antony V; Spahr J; Rubenstein RC; Moss RB; Herzenberg LA; Goss CH; Tirouvanziam R
    J Cyst Fibros; 2015 Mar; 14(2):219-27. PubMed ID: 25228446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of clarithromycin on airway obstruction and inflammatory markers in induced sputum in cystic fibrosis: a pilot study.
    Ordoñez CL; Stulbarg M; Grundland H; Liu JT; Boushey HA
    Pediatr Pulmonol; 2001 Jul; 32(1):29-37. PubMed ID: 11416873
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxidative stress and lipid-derived inflammatory mediators during acute exacerbations of cystic fibrosis.
    Reid DW; Misso N; Aggarwal S; Thompson PJ; Walters EH
    Respirology; 2007 Jan; 12(1):63-9. PubMed ID: 17207027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.